{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:09:05Z","timestamp":1772766545174,"version":"3.50.1"},"reference-count":87,"publisher":"Touch Medical Media, Ltd.","issue":"2","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"abstract":"<p\/>","DOI":"10.17925\/ee.2021.17.2.112","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T12:47:30Z","timestamp":1637412450000},"page":"112","source":"Crossref","is-referenced-by-count":4,"title":["Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice"],"prefix":"10.17925","volume":"17","author":[{"given":"Sherwyn","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Evolution Research Group, San Antonio, TX, USA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Lucas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Lucas Research, Moorehead City, NC, USA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark H","family":"DeLegge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"IQVIA, Raleigh, NC, USA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes due to non-alcoholic steatohepatitis compared to cirrhosis caused by hepatitis C.\n                      Hepatology\n                      . 2008;24:248\u201354.","DOI":"10.1111\/j.1440-1746.2008.05640.x"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bertot LC, Adams LA. The natural history of non-alcoholic fatty liver disease.\n                      Int J Mol Sci\n                      . 2016;29:774\u201385.","DOI":"10.3390\/ijms17050774"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Younassi ZM. The epidemiology of nonalcoholic steatohepatitis.\n                      Clin Liv Dis\n                      . 2018;11:92\u20134.","DOI":"10.1002\/cld.710"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Angulo P, Alba LM, Petrovic LM, et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease.\n                      J Hepatol\n                      . 2004;41:943\u20139.","DOI":"10.1016\/j.jhep.2004.08.020"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.\n                      Gastroenterology\n                      . 2011;140:124\u201331.","DOI":"10.1053\/j.gastro.2010.09.038"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Bril F, Barb D, Portillo-Sanchez P, et al. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.\n                      Hepatology\n                      . 2017;65:1132\u201344.","DOI":"10.1002\/hep.28985"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Masarone M, Federico A, Abenavoli L, et al. Non-alcoholic fatty liver: epidemiology and natural history.\n                      Rev Recent Clin Trials\n                      . 2014;9:126\u201333.","DOI":"10.2174\/1574887109666141216111143"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Smith SR, Lovejou LC, Greenway F, et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments and visceral adipose tissue to the metabolic complications of obesity.\n                      Metabolism\n                      . 2001;50:425\u201335.","DOI":"10.1053\/meta.2001.21693"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Kelley DE, Thaete FL, Troost F, et al. Subdivisions of subcutaneous adipose tissue and insulin resistance.\n                      Am J Physiol Endocrinol Metab\n                      . 2000;278:E941\u20138.","DOI":"10.1152\/ajpendo.2000.278.5.E941"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.\n                      Hepatology\n                      . 2012;13:1389\u201397.","DOI":"10.1002\/hep.25539"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Rosso C, Kazankov K, Younes R, et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.\n                      J Hepatol\n                      . 2019;71:1012\u201321.","DOI":"10.1016\/j.jhep.2019.06.031"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.\n                      Hepatology\n                      . 2010;52:1836\u201346.","DOI":"10.1002\/hep.24001"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Koo BK, Joo SK, Kim D, et al. Additive effects of PNPLA3 and TM6SF2 on the histologic severity of non-alcoholic fatty liver disease.\n                      J Gastroenterol Hepatol\n                      . 2017;33:1277\u201385.","DOI":"10.1111\/jgh.14056"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease specific mortality in NAFLD after up to 33 years of follow-up.\n                      Hepatology\n                      . 2015;61:1547\u201354.","DOI":"10.1002\/hep.27368"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Perazzo H, Munteanu M, Ngo Y, et al. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.\n                      Aliment Pharmacol Ther\n                      . 2014;40:1081\u201393.","DOI":"10.1111\/apt.12946"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Al Rifai M, Silverman MG, Nasir K, et al. Association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA).\n                      Atherosclerosis\n                      . 2015;239:629\u201333.","DOI":"10.1016\/j.atherosclerosis.2015.02.011"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative\/lasertreated retinopathy in type 2 diabetic patients.\n                      Diabetologia\n                      . 2008;51:444\u201350.","DOI":"10.1007\/s00125-007-0897-4"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus.\n                      Nat Rev Gastroenterol Hepatol\n                      . 2017;14:32\u201342.","DOI":"10.1038\/nrgastro.2016.147"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome: evidence from a systematic review and meta-analysis.\n                      J Gastroenterol Hepatol\n                      . 2016;31:936\u201344.","DOI":"10.1111\/jgh.13264"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Leite NC, Salles GF, Araujo AL, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus.\n                      Liver Int\n                      . 2009;29:113\u20139.","DOI":"10.1111\/j.1478-3231.2008.01718.x"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Lonardo A, Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome.\n                      Dig Liver Dis\n                      . 2015;47:181\u201390.","DOI":"10.1016\/j.dld.2014.09.020"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Portillo-Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels.\n                      J Clin Endocrinol Metab\n                      . 2015;100:2231\u20138.","DOI":"10.1210\/jc.2015-1966"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.\n                      Clin Gastroenterol Hepatol\n                      . 2015;13:643\u201354.","DOI":"10.1016\/j.cgh.2014.04.014"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.\n                      J Hepatol\n                      . 2015;62:1148\u201355.","DOI":"10.1016\/j.jhep.2014.11.034"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Vidal J, Ferrer JP, Estimates E, et al. Diabetes mellitus in patients with liver cirrhosis.\n                      Diabetes Res Clin Pract\n                      . 1994;25:19\u201325.","DOI":"10.1016\/0168-8227(94)90157-0"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"de Marco, R, Locatelli F, Zoppini G, et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study.\n                      Diabetes Care\n                      . 1999;22:756\u201361.","DOI":"10.2337\/diacare.22.5.756"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease.\n                      Hepatology\n                      . 2004;40:475\u201383.","DOI":"10.1002\/hep.20323"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.\n                      Hepatology\n                      . 2016;64:73\u201384.","DOI":"10.1002\/hep.28431"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients.\n                      Gastroenterology\n                      . 2015;149:379\u201388.","DOI":"10.1053\/j.gastro.2015.04.014"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.\n                      Gastroenterology\n                      . 2015;149:367\u201378.","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.\n                      Hepatology\n                      . 2004;40:1387\u201395.","DOI":"10.1002\/hep.20466"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease.\n                      Gastroenterology\n                      . 2002;122:1649\u201357.","DOI":"10.1053\/gast.2002.33573"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Klair JS, Yang JD, Abdelmalek MF, et al. Nonalcoholic Steatohepatitis Clinical Research Network. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease.\n                      Hepatology\n                      . 2016;64:85\u201391.","DOI":"10.1002\/hep.28514"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Gambineri A, Pelusi V, Vicennati V, et al. Obesity and polycystic ovary disease.\n                      Int J Obesity\n                      . 2002;26:883\u201396.","DOI":"10.1038\/sj.ijo.0801994"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Kauffman RP, Baker TE, Baker V, et al. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role?\n                      Gynecol Endocrinol\n                      . 2010;26:39\u201346.","DOI":"10.3109\/09513590903184084"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Barbieri RL, Makris A, Randall RW, et al. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism.\n                      J Clin Endocrinol Metab\n                      . 1986;62:904\u201310.","DOI":"10.1210\/jcem-62-5-904"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Kumarendran B, O'Reilly MW, Manolopoulos KN, et al. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database.\n                      PLoS Med\n                      . 2018;15:e1002542.","DOI":"10.1371\/journal.pmed.1002542"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Kupelian V, Page ST, Araujo AB, et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men.\n                      J Clin Endocrinol Metab\n                      . 2006;91:843\u201350.","DOI":"10.1210\/jc.2005-1326"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"El baba K, Azar ST. Low testosterone and diabetes.\n                      Curr Diabetes Rev\n                      . 2013;9:418\u201321.","DOI":"10.2174\/15733998113099990071"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Couillard C, Gagnon J, Bergeron J, et al. C. Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study.\n                      J Clin Endocrinol Metab\n                      . 2000;85:1026\u201331.","DOI":"10.1210\/jc.85.3.1026"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Kim S, Kwon H, Park J-H, et al. A low level serum total testosterone is independently associated with non-alcoholic fatty liver disease.\n                      BMC Gastroenterol\n                      . 2012;12:69.","DOI":"10.1186\/1471-230X-12-69"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Jaruvongvanich V, Sanguankeo A, Riangwiwat T, Upala S. Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis.\n                      Ann Hepatol\n                      . 2017;16:382\u201394.","DOI":"10.5604\/01.3001.0009.8593"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Bhattacharya RK, Khera M, Blick G, et al. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS).\n                      BMC Endocr Disord\n                      . 2011;11:18.","DOI":"10.1186\/1472-6823-11-18"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Hong JW, Kim JY, Kim YE, Lee EJ. Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men.\n                      Horm Metab Res\n                      . 2011;43:48\u201354.","DOI":"10.1055\/s-0030-1265217"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Koehler E, Swain J, Sanderson S, et al. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients.\n                      Liver Int\n                      . 2012;32:279\u201386.","DOI":"10.1111\/j.1478-3231.2011.02637.x"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease.\n                      Hepatology\n                      . 2009;50:1282\u201393.","DOI":"10.1002\/hep.23119"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Klieverik LP, Coomans CP, Endert E, et al. Thyroid hormone effects on whole-body energy homeostasis and tissue-specific fatty acid uptake in vivo.\n                      Endocrinology\n                      . 2009;150;5639\u201348.","DOI":"10.1210\/en.2009-0297"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Pagadala MR, Zein CO, Dasarathy S, et al. Prevalence of hypothyroidism in nonalcoholic fatty liver disease.\n                      Dig Dis Sci\n                      . 2012;57:528\u201334.","DOI":"10.1007\/s10620-011-2006-2"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches.\n                      Drugs\n                      . 2013;73:1\u201314.","DOI":"10.1007\/s40265-012-0004-0"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss \u2265 10 % is associated with improved fibrosis in patients with nonalcoholic steatohepatitis.\n                      Dig Dis Sci\n                      . 2015;60:1024\u201330.","DOI":"10.1007\/s10620-014-3380-3"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.\n                      Hepatology\n                      . 2010;51:121\u20139.","DOI":"10.1002\/hep.23276"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Uygun A, Kadayifci A, Sik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis.\n                      Aliment Pharmacol Ther\n                      . 2004;19:537\u201344.","DOI":"10.1111\/j.1365-2036.2004.01888.x"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Cui J, Philo L, Nguyen P, et al. Sitagliptin vs placebo for non-alcoholic fatty liver disease: a randomized controlled trial.\n                      J Hepatol\n                      . 2016;65:369\u201376.","DOI":"10.1016\/j.jhep.2016.04.021"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Takase T, Nakamura A, Miyoshi H, et al. Amelioration of fatty liver index in patients with type 2 diabetes on ipraglifozlin: an association with glucose-lowering effects.\n                      Endocr J\n                      . 2017;64:363\u20137.","DOI":"10.1507\/endocrj.EJ16-0295"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of a randomized placebo controlled fatty liver improvement with rosiglitazone (FLIRT).\n                      Gastroenterology\n                      . 2008;135:100\u201310.","DOI":"10.1053\/j.gastro.2008.03.078"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis.\n                      JAMA Intern Med\n                      . 2017;177:633\u201340.","DOI":"10.1001\/jamainternmed.2016.9607"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.\n                      JAMA\n                      . 2007;298:1180\u20138.","DOI":"10.1001\/jama.298.10.1180"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalchoholic liver disease and non-alcoholic steatohepatitis.\n                      Hepatology\n                      . 2018;68:361\u201371.","DOI":"10.1002\/hep.29724"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Townsend SA, Newsome PN. Review article: new treatments in non-alcoholic fatty liver disease.\n                      Aliment Pharmacol Ther\n                      . 2017;46:494\u2013507.","DOI":"10.1111\/apt.14210"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.\n                      Lancet\n                      . 2016;387:679\u201390.","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.\n                      Aliment Pharmacol Ther\n                      . 2013;37:234\u201342.","DOI":"10.1111\/apt.12149"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Kaul U, Parmar D, Manjunath K, et al. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.\n                      Cardiovasc Diabetol\n                      . 2019;18:80.","DOI":"10.1186\/s12933-019-0884-3"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Nelson A, Torres DM, Morgan AE, et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial.\n                      J Clin Gastroenterol\n                      . 2009;43:990\u20134.","DOI":"10.1097\/MCG.0b013e31819c392e"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.\n                      Hepatology\n                      . 2010;52:79\u2013104.","DOI":"10.1002\/hep.23623"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Lassailly G, Caiazzo R, Ntandja-Wandji L-C, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis.\n                      Gastroenterology\n                      . 2020;159:1290\u2013301.","DOI":"10.1053\/j.gastro.2020.06.006"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events.\n                      JAMA\n                      . 2012;307:56\u201365.","DOI":"10.1001\/jama.2011.1914"},{"key":"ref67","unstructured":"ClinicalTrials.gov. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE). ClinicalTrials.gov Identifier: NCT02548351. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02548351 (accessed 31 March 2021)."},{"key":"ref68","unstructured":"ClinicalTrials.gov. Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR-4). ClinicalTrials.gov Identifier: NCT03053063. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03053063 (accessed 31 March 2021)."},{"key":"ref69","unstructured":"ClinicalTrials.gov. Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR-3). ClinicalTrials.gov Identifier: NCT03053050. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03053050 (accessed 31 March 2021)."},{"key":"ref70","unstructured":"ClinicalTrials.gov. Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT). ClinicalTrials.gov Identifier: NCT02704403. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02704403 (accessed 31 March 2021)."},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.\n                      J Hepatol\n                      . 2012;56:234\u201340.","DOI":"10.1016\/j.jhep.2011.03.020"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study.\n                      Hepatology\n                      . 2005;42:44\u201352.","DOI":"10.1002\/hep.20734"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.\n                      Hepatology\n                      . 2007;45:846\u201354.","DOI":"10.1002\/hep.21496"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States.\n                      Am J Gastroenterol\n                      . 2003;98:960\u20137.","DOI":"10.1111\/j.1572-0241.2003.07486.x"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with non-alcoholic fatty liver disease.\n                      Gastroenterology\n                      . 2019;156:1264-81.e4.","DOI":"10.1053\/j.gastro.2018.12.036"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Gao X, Fan J-G, Study Group of Liver and Metabolism, Chinese Society of Endocrinology. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology.\n                      J Diabetes\n                      . 2013;4:406\u201315.","DOI":"10.1111\/1753-0407.12056"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Standards of medical care in diabetes - 2019 abridged for primary care providers.\n                      Clin Diabetes\n                      . 2019;37:11\u201334.","DOI":"10.2337\/cd18-0105"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.\n                      Obes Facts\n                      . 2016;9:65\u201390.","DOI":"10.1159\/000443344"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Petit JM, Cercueil J-P, Deimal D, et al. Effect of liraglutide therapy on liver fat content with inadequately controlled type-2 diabetes: the Lira-NAFLD study.\n                      J Clin Endocrinol Metab\n                      . 2017;102:407\u201315.","DOI":"10.1210\/jc.2016-2775"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"David JPE, Henry ZH, Argo CK, Northrup PG. Relationship of physician counseling to weight loss among patients with non-alcoholic liver disease: an observational cohort study using National Health and Education Survey data.\n                      Clin Liver Dis (Hoboken)\n                      . 2019;14:156\u201360.","DOI":"10.1002\/cld.832"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Targher G, Bertolini L, Rodella S, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men.\n                      Obesity\n                      . 2008;16:1394\u20139.","DOI":"10.1038\/oby.2008.64"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Shah AG, Lydecker A, Murray K, et al. Use of fib-4 index for non-invasive evaluation of fibrosis in non-alcoholic liver disease.\n                      Clin Gastroenterol Hepatol\n                      . 2009;7:1104\u20132.","DOI":"10.1016\/j.cgh.2009.05.033"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Adams LA, George J, Bugiones E, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.\n                      J Gastroenterol Hepatol\n                      . 2011;26:1536\u201343.","DOI":"10.1111\/j.1440-1746.2011.06774.x"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Wong VW, Adams LA, de Ledinghen V, et al. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise.\n                      Nat Rev Gastroenterol Hepatol\n                      . 2018;15:461\u201378.","DOI":"10.1038\/s41575-018-0014-9"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Katsagoni CN, Georgoulis M, Papatheodoridis GV, et al. Effects of lifestyle interventions on clinical characteristics of patients with nonalcoholic fatty liver disease: a meta-analysis.\n                      Metabolism\n                      . 2017;68:119\u201332.","DOI":"10.1016\/j.metabol.2016.12.006"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Koehler EM, Plompen EP, Schouten JN, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study.\n                      Hepatology\n                      . 2016;63:138\u201347.","DOI":"10.1002\/hep.27981"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Younossi ZR, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States.\n                      Clin Gastroenterol Hepatol\n                      . 2021;19:580\u20139.","DOI":"10.1016\/j.cgh.2020.05.064"}],"container-title":["touchREVIEWS in Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchendocrinology.com\/liver-disorders\/journal-articles\/non-alcoholic-steatohepatitis-from-pathophysiology-to-clinical-practice\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:59:39Z","timestamp":1764745179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchendocrinology.com\/liver-disorders\/journal-articles\/non-alcoholic-steatohepatitis-from-pathophysiology-to-clinical-practice\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"alternative-id":["EE.2021.17.2.112"],"URL":"https:\/\/doi.org\/10.17925\/ee.2021.17.2.112","relation":{},"ISSN":["1758-3772"],"issn-type":[{"value":"1758-3772","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}